Journal Article The atherosclerosis–cancer axis: the shared immunotherapeutic potential of CBL inhibition Get access Kai-Uwe Jarr, Kai-Uwe Jarr Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, Heidelberg, GermanyGerman Center for Cardiovascular Research (DZHK Partner Site Heidelberg/Mannheim), Heidelberg, Germany https://orcid.org/0000-0003-3376-6478 Search for other works by this author on: Oxford Academic PubMed Google Scholar Lingfeng Luo, Lingfeng Luo Department of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA https://orcid.org/0000-0002-0601-0053 Search for other works by this author on: Oxford Academic PubMed Google Scholar Nicholas J Leeper Nicholas J Leeper Department of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USAStanford Cardiovascular Institute, Stanford University, Stanford, CA, USADepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA Corresponding author. Tel: +1 650 724 8475, Email: email protected https://orcid.org/0000-0002-0905-2806 Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, ehaf624, https://doi.org/10.1093/eurheartj/ehaf624 Published: 09 September 2025
Jarr et al. (Tue,) studied this question.